Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: The therapeutic potential of a venomous lizard: the use of glucagon-like peptide-1 analogues in the critically ill
Author: Deane, A.
Chapman, M.
Horowitz, M.
Citation: Critical Care (UK), 2010; 14(5):1-3
Publisher: Current Science Ltd
Issue Date: 2010
ISSN: 1466-609X
Statement of
Adam M Deane, Marianne J Chapman and Michael Horowitz
Abstract: Glucagon-like peptide-1 (GLP-1), a principal mediator of the postprandial insulinotropic response in health, has a half-life of minutes. The saliva of the Gila monster contains exendin-4, a structural analogue of human GLP-1, but with a much longer half-life. A synthetic preparation of exendin-4, exenatide, is suitable for human use and effectively lowers glucose in ambulant type 2 diabetic patients. When compared with insulin, exenatide therapy is associated with a reduction in hypoglycaemic episodes and postprandial glycaemic excursions in this group. Accordingly, GLP-1 analogues are appealing therapies for hyperglycaemia in the critically ill patient and warrant further study.
Keywords: Venoms
Reptilian Proteins
Glucagon-Like Peptide 1
Description: Commentary
Rights: © 2010 BioMed Central Ltd
DOI: 10.1186/cc9281
Appears in Collections:Anaesthesia and Intensive Care publications
Aurora harvest

Files in This Item:
File Description SizeFormat 
hdl_62806.pdfPublished version128.51 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.